Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.80 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272384 | 1.00 | FLT3 (0.80) | FLT3MAPK8MAPK9TTKCCNB2 | |
| SCHEMBL12522894 | 0.90 | FLT3 (0.83) | FLT3MAPK8MAPK9CCNE2CCNE1 | |
| SCHEMBL12273002 | 0.90 | FLT3 (0.83) | FLT3MAPK8MAPK9CCNE2CCNE1 | |
| SCHEMBL12522705 | 0.89 | FLT3 (1.00) | FLT3MAPK8TTK | |
| SCHEMBL12272449 | 0.89 | FLT3 (1.00) | FLT3MAPK8TTK | |
| SCHEMBL12272016 | 0.88 | FLT3 (0.63) | FLT3MAPK8MAPK9 | |
| SCHEMBL12522895 | 0.88 | FLT3 (0.63) | FLT3MAPK8MAPK9 | |
| SCHEMBL12490674 | 0.85 | FLT3 (0.59) | FLT3MAPK8MAPK9CDK1CCNE1 | |
| SCHEMBL12522707 | 0.84 | FLT3 (0.71) | FLT3MAPK8MAPK9 | |
| SCHEMBL12272584 | 0.84 | FLT3 (0.71) | FLT3MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238564-A1 | IMIDAZO PYRAZINES | THPO, MCL1, IKZF3 | FLT3 5/4885MAPK8 3036/4885MAPK9 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.